Epigenetic Modulation of the Tumor Immune Microenvironment to Potentiate Immune Checkpoint Blockade Therapy.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
entrez:
7
2
2020
pubmed:
7
2
2020
medline:
9
7
2020
Statut:
ppublish
Résumé
Response rates to immune checkpoint blockade (ICB) in KRAS-mutant lung adenocarcinoma remain poor. In this issue of
Identifiants
pubmed: 32024681
pii: 10/2/179
doi: 10.1158/2159-8290.CD-19-1349
doi:
Substances chimiques
ASF1A protein, human
0
Cell Cycle Proteins
0
KRAS protein, human
0
Molecular Chaperones
0
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-181Subventions
Organisme : NIGMS NIH HHS
ID : R35 GM128720
Pays : United States
Commentaires et corrections
Type : CommentOn
Informations de copyright
©2020 American Association for Cancer Research.
Références
Singh H, Longo DL, Chabner BA. Improving prospects for targeting RAS. J Clin Oncol. 2015;33:3650–9.
Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.
Li F, Huang Q, Luster TA, Hu H, Zhang H, Ng W-L, et al. In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma. Cancer Discov. 2020;10:270–87.
Swoboda A, Nanda R. Immune checkpoint blockade for breast cancer. Cancer Treat Res. 2018;173:155–65.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
Wu Y, Li X, Yu J, Björkholm M, Xu D. ASF1a inhibition induces p53-dependent growth arrest and senescence of cancer cells. Cell Death Dis. 2019;10:76.
Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48:417–33.
Liang X, Yuan X, Yu J, Wu Y, Li K, Sun C, et al. Histone chaperone ASF1A predicts poor outcomes for patients with gastrointestinal cancer and drives cancer progression by stimulating transcription of β-catenin target genes. EBioMedicine. 2017;21:104–16.
O'Sullivan RJ, Arnoult N, Lackner DH, Oganesian L, Haggblom C, Corpet A, et al. Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1. Nat Struct Mol Biol. 2014;21:167–74.
Zabaronick SR, Tyler JK. The histone chaperone anti-silencing function 1 is a global regulator of transcription independent of passage through S phase. Mol Cell Biol. 2005;25:652–60.